Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

Authors: Parisi, Claudia, Benitez, José Carlos, Lecourt, Hélène, dall’Olio, Filippo Gustavo, Aldea, Mihaela, Blanc-Durand, Felix, Vergé, Véronique, Quivoron, Cyril, Naltet, Charles, Abdayem, Pamela, Lavaud, Pernelle, Ghigna, Maria Rosa, Friboulet, Luc, Loriot, Yohann, De Botton, Stéphane, Ribrag, Vincent, Ardizzoni, Andrea, Planchard, David, Soria, Jean-Charles, Barlesi, Fabrice, Besse, Benjamin

Source: In The Journal of Liquid Biopsy December 2024 6

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Authors: DiNardo, Courtney D., Roboz, Gail J., Watts, Justin M., Madanat, Yazan F., Prince, Gabrielle T., Baratam, Praneeth, de Botton, Stéphane, Stein, Anthony, Foran, James M., Arellano, Martha L., Sallman, David A., Hossain, Mohammad, Marchione, Dylan M., Bai, Xiaofei, Patel, Prapti A., Kapsalis, Stephanie M., Garcia-Manero, Guillermo, Fathi, Amir T.

Source: In Blood Advances 13 August 2024 8(15):4209-4220

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Authors: Montesinos, Pau, Fathi, Amir T., de Botton, Stéphane, Stein, Eytan M., Zeidan, Amer M., Zhu, Yue, Prebet, Thomas, Vigil, Carlos E., Bluemmert, Iryna, Yu, Xin, DiNardo, Courtney D.

Source: In Blood Advances 28 May 2024 8(10):2509-2519

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Authors: Risueño, Alberto, See, Wendy L., Bluemmert, Iryna, de Botton, Stéphane, DiNardo, Courtney D., Fathi, Amir T., Schuh, Andre C., Montesinos, Pau, Vyas, Paresh, Prebet, Thomas, Gandhi, Anita, Hasan, Maroof

Source: In Leukemia Research May 2024 140

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Authors: Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, Zeidan, Amer M ^*

Source: In The Lancet Haematology September 2023 10(9):e767-e776

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Authors: Vasseur, Loïc, Fenwarth, Laurène, Lambert, Jérôme, de Botton, Stéphane, Figeac, Martin, Villenet, Céline, Heiblig, Maël, Dumas, Pierre-Yves, Récher, Christian, Berthon, Céline, Lemasle, Emilie, Lebon, Delphine, Lambert, Juliette, Terré, Christine, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Cheok, Meyling, Itzykson, Raphael, Duployez, Nicolas

Source: In Blood Advances 8 August 2023 7(15):4024-4034

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Authors: de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C., Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra K., Jurcic, Joseph G., Krauter, Jürgen, Thomas, Xavier, Watts, Justin M., Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, Cortes, Jorge

Source: In Blood Advances 11 July 2023 7(13):3117-3127

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Authors: de Botton, Stéphane ^∗, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel J., Rousselot, Philippe, Rizzieri, David A., Liesveld, Jane L., Fenaux, Pierre, Braun, Thorsten, Banos, Anne, Jurcic, Joseph G., Sekeres, Mikkael A., Savona, Michael R., Roboz, Gail J., Bixby, Dale, Madigan, Kate, Volkert, Angela, Stephens, Kristin, Kang-Fortner, Qing, Baker, Kristen, Paul, Sofia, McKeown, Michael, Carulli, John, Eaton, Matthew, Hodgson, Graeme, Fiore, Christopher, Kelly, Michael J., Roth, David A., Stein, Eytan M.

Source: In Blood Advances 9 May 2023 7(9):1858-1870

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Authors: de Botton, Stéphane ^∗, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, DiNardo, Courtney D.

Source: In Blood 12 January 2023 141(2):156-167

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Authors: Watts, Justin M ^*, Baer, Maria R, Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J, Dinner, Shira N, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S, Seiter, Karen P, Wei, Andrew H, De Botton, Stephane, Arnan, Montserrat, Donnellan, Will, Schwarer, Anthony P, Récher, Christian, Jonas, Brian A, Ferrell, P Brent, Jr, Marzac, Christophe, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie M, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, Cortes, Jorge E

Source: In The Lancet Haematology January 2023 10(1):e46-e58

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.

Authors: De Botton, Stéphane^1,2 (AUTHOR) stephane.debotton@gustaveroussy.fr, Récher, Christian³ (AUTHOR), Cortes, Jorge⁴ (AUTHOR), Curti, Antonio⁵ (AUTHOR), Fenaux, Pierre⁶ (AUTHOR), Peterlin, Pierre⁷ (AUTHOR), Pigneux, Arnaud⁸ (AUTHOR), Yee, Karen⁹ (AUTHOR), Wei, Andrew¹⁰ (AUTHOR), Mims, Alice¹¹ (AUTHOR), Schiller, Gary¹² (AUTHOR), Chao, Mwe Mwe¹³ (AUTHOR), Tian, Hua¹³ (AUTHOR), Watts, Justin M.¹⁴ (AUTHOR)

Source: British Journal of Haematology. Apr2025, Vol. 206 Issue 4, p1121-1128. 8p.

Subject Terms: *ACUTE myeloid leukemia, *MYELOPROLIFERATIVE neoplasms, *THERAPEUTICS, *GENETIC mutation, *AZACITIDINE, *TREATMENT effectiveness

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group

Authors: Michallet, Mauricette, Sobh, Mohamad, Morisset, Stephane, Deloire, Alexandre, Raffoux, Emmanuel, de Botton, Stephane, Caillot, Denis, Chantepie, Sylvain, Girault, Stephane, Berthon, Celine, Bertoli, Sarah, Lepretre, Stephane, Leguay, Thibaut, Castaigne, Sylvie, Marolleau, Jean-Pierre, Pautas, Cecile, Malfuson, Jean-Valere, Veyn, Norbert, Braun, Thorsten, Gastaud, Lauris, Suarez, Felipe, Schmidt, Aline, Gressin, Remy, Bonmati, Caroline, Celli-Lebras, Karine, El-Hamri, Mohamed, Ribaud, Patricia, Dombret, Herve, Thomas, Xavier, Bergeron, Anne

Source: In Clinical Lymphoma, Myeloma and Leukemia May 2022 22(5):311-318

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Authors: DiNardo, Courtney D ^{a, *}, Schuh, Andre C ^b, Stein, Eytan M ^c, Montesinos, Pau ^d, Wei, Andrew H ^e, de Botton, Stéphane ^f, Zeidan, Amer M ^g, Fathi, Amir T ^h, Kantarjian, Hagop M ^a, Bennett, John M ⁱ, Frattini, Mark G ^j, Martin-Regueira, Patricia ^j, Lersch, Frederik ^k, Gong, Jing ^j, Hasan, Maroof ^j, Vyas, Paresh ^{l, †}, Döhner, Hartmut ^{m, †}

Source: In The Lancet Oncology November 2021 22(11):1597-1608

SOHO State of the Art Updates and Next Questions: IDH Inhibition

Authors: Dragani, Matteo, de Botton, Stéphane

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2021 21(9):567-572

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study

Authors: Duchmann, Matthieu, Micol, Jean-Baptiste, Duployez, Nicolas, Raffoux, Emmanuel, Thomas, Xavier, Marolleau, Jean-Pierre, Braun, Thorsten, Adès, Lionel, Chantepie, Sylvain, Lemasle, Emilie, Berthon, Céline, Malfuson, Jean-Valère, Pautas, Cécile, Lambert, Juliette, Boissel, Nicolas, Celli-Lebras, Karine, Caillot, Denis, Turlure, Pascal, Vey, Norbert, Pigneux, Arnaud, Recher, Christian, Terré, Christine, Gardin, Claude, Itzykson, Raphaël, Preudhomme, Claude, Dombret, Hervé, de Botton, Stéphane

Source: In Blood 20 May 2021 137(20):2827-2837

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Authors: Fenwarth, Laurène, Thomas, Xavier, de Botton, Stéphane, Duployez, Nicolas, Bourhis, Jean-Henri, Lesieur, Auriane, Fortin, Gael, Meslin, Paul-Arthur, Yakoub-Agha, Ibrahim, Sujobert, Pierre, Dumas, Pierre-Yves, Récher, Christian, Lebon, Delphine, Berthon, Céline, Michallet, Mauricette, Pigneux, Arnaud, Nguyen, Stéphanie, Chantepie, Sylvain, Vey, Norbert, Raffoux, Emmanuel, Celli-Lebras, Karine, Gardin, Claude, Lambert, Juliette, Malfuson, Jean-Valère, Caillot, Denis, Maury, Sébastien, Ducourneau, Benoît, Turlure, Pascal, Lemasle, Emilie, Pautas, Cécile, Chevret, Sylvie, Terré, Christine, Boissel, Nicolas, Socié, Gérard, Dombret, Hervé, Preudhomme, Claude ^*, Itzykson, Raphael ^{*, *}

Source: In Blood 28 January 2021 137(4):524-532

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

Authors: Cortes, Jorge E., Roboz, Gail J., Baer, Maria R., Jonas, Brian A., Schiller, Gary J., Yee, Karen, Ferrell, P. Brent, Yang, Jay, Wang, Eunice S., Blum, William G., Mims, Alice, Tian, Hua, Sheppard, Aaron, de Botton, Stéphane, Montesinos, Pau, Curti, Antonio, Watts, Justin M.

Source: Journal of Hematology & Oncology; 1/16/2025, Vol. 18 Issue 1, p1-13, 13p

Subject Terms: BLOOD cell count, HEMATOPOIETIC stem cells, ACUTE myeloid leukemia, ERYTHROCYTES, STEM cell transplantation

Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023.

Authors: Guerra, Matteo, Alouani, Emily, Hueso, Thomas, Ouali, Kaissa, Danu, Alina, Hollebecque, Antoine, Bahleda, Rastislav, Willekens, Christophe, Gazzah, Anas, Baldini, Capucine, Postel‐Vinay, Sophie, Micol, Jean‐Baptiste, Massard, Christophe, De Botton, Stéphane, Ribrag, Vincent, Michot, Jean‐Marie

Source: European Journal of Haematology; Jan2025, Vol. 114 Issue 1, p89-97, 9p

Subject Terms: ACUTE myeloid leukemia, HEMATOLOGIC malignancies, MULTIPLE myeloma, HODGKIN'S disease, MYELODYSPLASTIC syndromes

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

Authors: Fagnan, Alexandre ^{1, 2}, Bagger, Frederik Otzen ^{3, 4, 5, 6, *}, Piqué-Borràs, Maria-Riera ^{3, 4, *}, Ignacimouttou, Cathy ^{1, 2, *}, Caulier, Alexis ^{7, 8}, Lopez, Cécile K. ^{1, 2}, Robert, Elie ^{1, 2}, Uzan, Benjamin ⁹, Gelsi-Boyer, Véronique ^{10, 11}, Aid, Zakia ^{1, 2}, Thirant, Cécile ^{1, 2}, Moll, Ute ^{12, 13}, Tauchmann, Samantha ^{3, 4}, Kurtovic-Kozaric, Amina ¹⁴, Maciejewski, Jaroslaw ¹⁵, Dierks, Christine ¹⁶, Spinelli, Orietta ¹⁷, Salmoiraghi, Silvia ^{17, 18}, Pabst, Thomas ¹⁹, Shimoda, Kazuya ²⁰, Deleuze, Virginie ^{21, 22}, Lapillonne, Hélène ²³, Sweeney, Connor ²⁴, De Mas, Véronique ²⁵, Leite, Betty ²⁶, Kadri, Zahra ²⁷, Malinge, Sébastien ^{1, 28}, de Botton, Stéphane ^{1, 2}, Micol, Jean-Baptiste ¹, Kile, Benjamin ²⁹, Carmichael, Catherine L. ²⁹, Iacobucci, Ilaria ³⁰, Mullighan, Charles G. ^{30, 31}, Carroll, Martin ³², Valent, Peter ^{33, 34}, Bernard, Olivier A. ^{1, 2}, Delabesse, Eric ²⁵, Vyas, Paresh ²⁴, Birnbaum, Daniel ^{10, 11}, Anguita, Eduardo ^{35, 36, 37, 38}, Garçon, Loïc ^{7, 8}, Soler, Eric ^{21, 22}, Schwaller, Juerg ^{2, 3, 4, †}, Mercher, Thomas ^{1, 1, 2, †}

Source: In Blood 6 August 2020 136(6):698-714

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Authors: Gardin, Claude, Pautas, Cécile, Fournier, Elise, Itzykson, Raphaël, Lemasle, Emilie, Bourhis, Jean-Henri, Adès, Lionel, Marolleau, Jean-Pierre, Malfuson, Jean-Valère, Gastaud, Lauris, Raffoux, Emmanuel, Lambert, Juliette, Braun, Thorsten, Thomas, Xavier, Chantepie, Sylvain, Cluzeau, Thomas, de Botton, Stéphane, Berthon, Céline, Boissel, Nicolas, Duployez, Nicolas, Terré, Christine, Peffault de Latour, Régis, Michallet, Mauricette, Celli-Lebras, Karine, Preudhomme, Claude, Dombret, Hervé

Source: In Blood Advances 12 May 2020 4(9):1942-1949